Proprietary TCR-NK Platform
Undisclosed Solid Tumors
PreclinicalActive; CTA submitted Q4 2025
Key Facts
Indication
Undisclosed Solid Tumors
Phase
Preclinical
Status
Active; CTA submitted Q4 2025
Company
About Zelluna Immunotherapy
Zelluna Immunotherapy's mission is to eliminate solid cancers by pioneering TCR-guided NK cell therapies. The company achieved a pivotal transformation in March 2025 by merging with Ultimovacs ASA, securing a public listing (OSE: ZLNA) and an infusion of capital to refocus entirely on its proprietary TCR-NK platform. Its strategy centers on developing scalable, allogeneic 'off-the-shelf' cell therapies that aim to combine precise tumor targeting with a favorable safety profile to address the vast, underserved solid tumor market.
View full company profileTherapeutic Areas
Other Undisclosed Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| Macrophage-Targeting Agonist Antibody | Bolt Biotherapeutics | Phase 1 |
| IMA204 | Immatics Biotechnologies | Phase 1 |
| TAR002 | TargImmune Therapeutics | Pre-clinical |
| TAR003 | TargImmune Therapeutics | Pre-clinical |
| ERAS-113 | Erasca | Discovery |
| Multiple Programs | Aktis Oncology | Discovery |
| BAT5506 | Compugen | Preclinical |
| Precision DACs | Prelude Therapeutics | Discovery |
| V2ACT Immunotherapy | Genelux | Phase 1 |
| ATOR-4066 | Alligator Bioscience AB | Discovery/Preclinical |
| ACR-6840 | Acrivon Therapeutics | Preclinical |
| ADC Program | Lantern Pharma | Discovery/Preclinical |